BBNX

Beta Bionics, Inc. 10-K Summary (Fiscal Year Ended December 31, 2024)

Business Context and Reporting Period

Beta Bionics, Inc. is a commercial-stage medical device company focused on the iLet Bionic Pancreas, an FDA-cleared automated insulin delivery system for Type 1 Diabetes (T1D). The iLet utilizes adaptive closed-loop algorithms to autonomously determine insulin doses without requiring carbohydrate counting. The company began commercializing the iLet in May 2023. This filing covers the fiscal year ended December 31, 2024. The company completed its Initial Public Offering (IPO) on January 31, 2025, listing on the Nasdaq Global Market under the symbol "BBNX."

Key Financial Metrics

Note: The company reported a net loss of $54.8 million for 2024, driven by significant investments in sales, marketing, and R&D, as well as a $13.4 million non-cash charge related to the change in fair value of warrant liabilities.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 443% year-over-year, driven by a full year of commercial sales compared to a partial year in 2023. The installed customer base grew nearly 5x, from 2,304 units in 2023 to 15,298 units in 2024.
• Expense Expansion: Operating expenses nearly doubled to $81.1 million. Sales and marketing expenses increased 100% to $37.1 million due to headcount growth, and R&D expenses increased 46% to $26.2 million, including $3.5 million in milestone payments to Xeris Pharmaceuticals for bihormonal development.
• Reimbursement Mix: Sales through the Pharmacy Benefit Plan (PBP) channel increased from 6% of net sales in 2023 to 10% in 2024. The company notes that while PBP sales generate lower upfront revenue, they are expected to yield higher lifetime value.
• Capital Structure: In November 2024, the company raised approximately $60.0 million in a Series E preferred stock financing. In January 2025, the company completed its IPO and a concurrent private placement, raising aggregate net proceeds of approximately $206 million.

Guidance, Outlook, and Risks

Outlook and Strategy: Management expects expenses to continue increasing as the company scales commercial operations, expands into primary care physician markets, and advances its product pipeline. The company estimates its current cash position, combined with IPO proceeds, will fund operations through the first half of 2028. Strategic priorities include expanding the PBP reimbursement channel and developing a patch pump and bihormonal iLet (insulin and glucagon).

Key Risks and Contingencies:

• Regulatory Oversight: The iLet is subject to a mandatory FDA post-market surveillance order (Section 522), requiring a one-year prospective study of 1,875 users to assess safety and effectiveness. Failure to meet these requirements could result in recall or withdrawal of the device.
• Single Product Dependence: The company relies entirely on the iLet for revenue. Any safety issues, manufacturing defects, or loss of market acceptance would materially harm the business.
• Supply Chain: The company relies on single-source suppliers for critical components (infusion sets, cartridge connectors, and pump motors). Disruptions could halt production.
• Reimbursement Uncertainty: Success depends on securing and maintaining coverage from third-party payors. Changes in reimbursement rates or policies could impact profitability.
• Profitability: The company has incurred losses since inception and expects to continue incurring losses for the foreseeable future.

Investor Verification Checklist

• Installed Base Growth: Verify the sustainability of the 5x growth in installed base (15,298 units) and the rate of new patient starts (12,994 in 2024).
• Reimbursement Mix: Monitor the shift from Durable Medical Equipment (DME) to Pharmacy Benefit Plan (PBP) channels and its impact on gross margins and cash flow timing.
• FDA Surveillance Study: Track the progress and results of the mandatory FDA post-market surveillance study required by the Section 522 order.
• Supply Chain Resilience: Assess the company's progress in qualifying alternative suppliers for single-source components to mitigate production risks.
• Cash Burn Rate: Evaluate the runway provided by the $103.6 million cash balance (pre-IPO) plus the ~$206 million in IPO proceeds against the projected operating expenses through 2028.
• Product Pipeline: Monitor development milestones for the bihormonal iLet and patch pump, including the $3.0 million milestone payment already made to Xeris.